WILMINGTON, N.C.--(BUSINESS WIRE)--Pharmaceutical Product Development, LLC (PPD) today announced the company has been recognized with awards for excellence in multimedia and digital communications that demonstrate the importance of clinical research in developing life-changing medical treatments. PPD recently earned four Telly Awards and three Web Health Awards.
“Multimedia platforms are powerful tools we use to educate, enlighten and inspire people about clinical research and the mission, vision and values of PPD,” said Elizabeth Kuronen, PPD’s vice president of strategic communications and marketing. “As a gateway to understanding PPD and the important work we do, our digital presence must be engaging to a broad range of stakeholders. These awards highlight PPD’s commitment to spreading the word about life-saving clinical trials.”
PPD earned two Telly Awards for “PPD Brings Life-changing Therapies to Market,” a video featuring company employees describing their passion for clinical research. The company also received two Bronze Telly Awards for a video exploring a state-of-the-art, current Good Manufacturing Practice (cGMP) facility, the “PPD cGMP Laboratory Tour” video.
PPD earned a Web Health Award for the company’s main website, which details clinical research service offerings, therapeutic expertise and the drug development process. The Web Health Awards also recognized the PPD Beach2Battleship Triathlon microsite and mobile site, which showcases PPD’s annual iron-distance triathlon and signature public education campaign spotlighting the role clinical trials play in improving health and saving lives.
The Telly Awards, founded in 1979, honor outstanding commercials, programs, videos and films, and receive more than 12,000 annual entries that are judged by advertising and production professionals to recognize distinction in creative work. Now in its 16th year, the Web Health Awards program celebrates high-quality digital resources for consumers and health professionals as determined by a panel of industry professionals who review hundreds of entries based on content, format and success in reaching the target audience.
PPD is a leading global contract research organization providing drug discovery, development, lifecycle management and laboratory services. Our clients and partners include pharmaceutical, biotechnology, medical device, academic and government organizations. With offices in 46 countries and approximately 13,000 professionals worldwide, PPD applies innovative technologies, therapeutic expertise and a commitment to quality to help clients and partners accelerate the delivery of safe and effective therapeutics and maximize the returns on their R&D investments. For more information, visit www.ppdi.com.
Except for historical information, all of the statements, expectations and assumptions, including statements, expectations and assumptions about PPD’s communications awards and their potential value, contained in this news release are forward-looking statements that involve a number of risks and uncertainties. Although PPD attempts to be accurate in making these forward-looking statements, it is possible that future circumstances might differ from the assumptions on which such statements are based and could cause actual results to differ materially from the forward-looking statements. Other important factors that could cause future results to differ materially include the following: rapid technological advances that make our services or capabilities less competitive; the ability to attract, integrate, retain and train key personnel; competition in the outsourcing industry; risks associated with acquisitions and investments; PPD’s ability to win new business; the ability to control SG&A spending; compliance with drug development regulations; changes in the regulation of the drug development process; overall global economic conditions; economic conditions, research and development spending, and outsourcing trends in the pharmaceutical, biotechnology and government-sponsored research sectors; consolidation in the pharmaceutical and biotechnology industries; loss, delay or modification of large contracts; higher-than-expected cancellation rates; the rate of conversion of backlog into revenue; risks associated with and dependence on strategic relationships; and actual operating performance. PPD assumes no obligation and expressly disclaims any duty to update these forward-looking statements in the future, except as required by applicable law. These forward-looking statements should not be relied upon as representing PPD’s estimates or views as of any date subsequent to the date hereof.